|

Psychedelic Spotlight Interview With Ronan Levy – Part 2

ByDavid Flores
Microdosing Psychedelics Recent Rediscovery

Similar Posts

  • Interview With Laura Dawn

    Listen, Podcasts

    In today’s episode of the Psychedelic Spotlight podcast, we feature Laura Dawn- a microdosing mentor, visionary life coach, business consultant, author, international speaker, and host of the Psychedelic Leadership podcast.

  • How Clinical Trials Work and Who is WINNING the Race (FOR NOW) // MAPS, CMPS, MNMD & more

    Listen, Videos

    Who’s winning the psychedelics race and how do clinical trials work? This topic has been requested a lot lately so we decided to give you a rundown on the clinical trials system and the psychedelic-inspired companies who are furthest advanced at the moment. Of course, for now, MAPS is leading the race. However, other public companies such as Compass Pathways (CMPS) and MindMed (MMED / MNMD) are not far behind, for now.

    Hopefully, this introductory video will help some new retail investors who are considering investing in biotech companies who do not te have an approved drug, to understand the importance that clinical trials need to play in their investing decisions.

    Timestamps:
    0:00 – Intro
    1:34 – What is the clinical trial system?
    2:15 – Preclinical
    3:00 – Phase 0
    3:32 – Phase I
    5:45 – Phase II
    8:26 – Phase III
    10:28 – Phase IV
    11:08 – Who’s winning the race?
    11:16 – MAPS ( non-for-profit entity): Has already completed a Phase III study on MDMA to treat PTSD
    12:02 – Compass Pathways (CMPS) has a Phase IIb trial to treat TRD with COMP360
    12:28 – MindMed (MMED / MNMD) has completed a Phase IIa LSD study to treat Anxiety and will begin phase IIb this year. MindMed also has other Phase II studies involving LSD & Ibogaine (18-MC)
    13:23 – Mydecine (MYCO) and CYBIN (CYBN) following suit

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Facebook: @thepsychedelicinvestor
    editing by: @themyaholy
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #Numi #CMPS

  • Interview With Nick Levich

    Listen, Podcasts

    Psychedelic Passage’s Co-Founder and Facilitator, Nick Levich, talks about the function, purpose and importance of a trip sitter during a psychedelic experience.

  • How to Legally Access Psychedelic Therapy in Canada | The Psychedelic Investor

    Listen, Videos

    How can someone legally access psychedelic therapy in Canada? This is the question that I ask David Harder, Founder and Co-CEO of ATMA.

    Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20

    Not only will this be your chance to meet me, but also the legendary Paul Stamets!

    Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…

    Follow us on Twitter:
    James: @Psy_Invest
    Maria: @psy_holy
    The Psychedelic Investor: @PsycInvestor
    Psychedelic Spotlight: @PsycSpotlight

    Follow us on Instagram:
    @thepsychedelicinvestor
    @psycspotlight

    To learn more about the emerging psychedelic industry, visit:
    https://psychedelicspotlight.com/

    By now, most people watching this video are probably aware of the potential for psychedelic medicines, when combined with therapy, such as psilocybin and MDMA to treat a variety of mental health conditions. But receiving this treatment is still difficult.

    In Canada, in addition to clinical trials, there are a couple of avenues that a patient can go through to receive psychedelic therapy. The first is called the Section 56 exemption, which has allowed dozens of people suffering from anxiety relating to terminal illnesses to undergo psilocybin therapy.

    There is also a new avenue called the Health Canada “Special Access Program”, though relatively few people have gone through that route so far.

    In the interview, we also discuss David’s company, ATMA. ATMA is a company that trains therapists to conduct psychedelic therapies. They also conduct therapy themselves.

    Lastly, we discuss the upcoming Catalyst Psychedelic conference, happening in Kingston, Ontario between May 20-23rd. I will be there, and I hope to see you also!